Log in
Enquire now
‌

US Patent 9598370 Prolyl hydroxylase inhibitors and methods of use

Patent 9598370 was granted and assigned to Akebia Therapeutics on March, 2017 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Akebia Therapeutics
Akebia Therapeutics
Current Assignee
Akebia Therapeutics
Akebia Therapeutics
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
9598370
Date of Patent
March 21, 2017
Patent Application Number
14854080
Date Filed
September 15, 2015
Patent Citations Received
‌
US Patent 11883386 Prolyl hydroxylase inhibitors and methods of use
0
‌
US Patent 11690836 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
0
‌
US Patent 11713298 Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
0
‌
US Patent 11857543 Compositions and methods for treating anemia
0
Patent Primary Examiner
‌
Noble Jarrell
Patent abstract

The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9598370 Prolyl hydroxylase inhibitors and methods of use

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.